Dark Horse Consulting and KunTuo Partner to Accelerate CGT Trials
WALNUT CREEK, Calif., and BEIJING, China, May 11, 2026 Dark Horse Consulting Group (DHCG) and KunTuo Medical Research and...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
WALNUT CREEK, Calif., and BEIJING, China, May 11, 2026 Dark Horse Consulting Group (DHCG) and KunTuo Medical Research and...
Shanghai, China – September 11, 2025 – Shanghai Zhimeng Biopharma, Inc. today announced that its investigational therapy CB03-154, a...
